

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	CBIO LIMITED
ABN	76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	MR STEPHEN JONES
Date of last notice	23 MARCH 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct – Mr Stephen Jones Indirect- described below
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. Stephen George Burch Jones & Nadine Jones <S & N Super Fund A/C> 2. Australian Technology Innovation Fund Limited. 3. Australian Biofunds Investments Limited 4. Emrold Pty Ltd <ATF Jones Family Trust> <p>Mr Jones is a beneficiary of the S & N Super Fund (at 1 above) and is a Director and shareholder of the entities identified at 2,3&4.</p>
Date of change	3 November 2010

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ol style="list-style-type: none"> 1. Stephen Jones 39 ordinary shares 2. Stephen George Burch Jones & Nadine Jones <S & N Super Fund A/C> 1,190,000 ordinary shares and 300,000 share options 3. Australian Technology Innovation Fund Limited 368,755 ordinary shares 4. Australian Biofunds Investments Limited 199,553 ordinary shares 5. Emrold Pty Ltd < ATF Jones Family Trust > 424,520
Class	Ordinary
Number acquired	Stephen George Burch Jones & Nadine Jones <S & N Super Fund A/C> 125,000 ordinary shares
Number disposed	nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$0.16 per share
No. of securities held after change	<ol style="list-style-type: none"> 1. Stephen Jones 39 ordinary shares 2. Stephen George Burch Jones & Nadine Jones <S & N Super Fund A/C> 1,315,000 ordinary shares and 300,000 share options 3. Australian Technology Innovation Fund Limited 368,755 ordinary shares 4. Australian Biofunds Investments Limited 199,553 ordinary shares 5. Emrold Pty Ltd < ATF Jones Family Trust > 424,520
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Shares acquired by Mr Jones as part of a Rights Issue conducted by CBio Limited.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a

+ See chapter 19 for defined terms.

Appendix 3Y
Change of **Director's Interest Notice**

Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity	CBIO LIMITED
ABN	76 094 730 417

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	DR MICHAEL MONSOUR
Date of last notice	23 March 2010

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct: Dr Michael Monsour Indirect: Described below
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	<ol style="list-style-type: none"> 1. MP Monsour Medical Practice Pty Ltd <MP Monsour Medical Practice Superannuation Fund A/C> 2. MPAMM Pty Ltd 3. Australian Technology Innovation Fund Limited. 4. Australian Biofunds Investments Limited <p>Dr Monsour is a Director and shareholder of the entities identified above.</p>
Date of change	3November 2010

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. of securities held prior to change	<ol style="list-style-type: none"> 1. Dr Michael Monsour 38,187 ordinary shares 2. MP Monsour Medical Practice Pty Ltd <MP Monsour Medical Practice Superannuation Fund A/C> 1,057,480 ordinary shares and 1,490,000 share options 3. MPAMM Pty Ltd 4,307,590 ordinary shares and 1,614,000 share options 4. Australian Technology Innovation Fund Limited 368,755 ordinary shares 5. Australian Biofunds Investments Limited 199,755 ordinary shares 6. Dr Michael Monsour <Spyder Foundation A/C> 337,843
Class	Ordinary
Number acquired	<ol style="list-style-type: none"> 1. Dr Michael Monsour 27,277 ordinary shares 2. MP Monsour Medical Practice Pty Ltd <MP Monsour Medical Practice Superannuation Fund A/C> 750,149 ordinary shares 3. MPAMM Pty Ltd 3,076,851 ordinary shares
Number disposed	337,843 shares (refer below for details on nature of disposal)
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Acquired: \$0.16 per share Disposal: nil
No. of securities held after change	<ol style="list-style-type: none"> 1. Dr Michael Monsour 65,464 ordinary shares 2. MP Monsour Medical Practice Pty Ltd <MP Monsour Medical Practice Superannuation Fund A/C> 1,807,629 ordinary shares and 1,490,000 share options 3. MPAMM Pty Ltd 7,384,441 ordinary shares and 1,614,000 share options 4. Australian Technology Innovation Fund Limited 368,755 ordinary shares 5. Australian Biofunds Investments Limited 199,755 ordinary shares

+ See chapter 19 for defined terms.

<p>Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</p>	<p>Dr Monsour and associated entities acquired 3,854,277 shares, totalling \$616,684, as part of a Rights Issue conducted by CBio Limited.</p> <p>The 'disposal' of shares relates to the correction of an administrative error on the share register. As advised to the market on 25 March, Dr Monsour was incorrectly recorded as the registered holder of the a parcel of CBio shares. The disposal of 337,843 shares on this notice does not represent a sale of shares but reflects the correction of an administrative error.</p>
---	---

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	n/a
Interest acquired	n/a
Interest disposed	n/a
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	n/a
Interest after change	n/a

+ See chapter 19 for defined terms.